Senhwa Biosciences Announces Completion of Enrollment in Phase 1b Trial for CX-5461: A Look at Their Next Steps

Senhwa Completes Enrollment in Phase 1b Expansion Trial for CX-5461

Taipei, Aug 25, 2026 – Senhwa Biosciences, Inc. (TPEx: 6492) announced a significant milestone today, marking the completion of patient enrollment in its Phase 1b expansion trial that focuses on the investigational drug pidnarulex, also known as CX-5461. This clinical study is evaluating the drug's efficacy as monotherapy for patients suffering from advanced solid tumors with specific genetic alterations linked to homologous recombination deficiency (HRD).

The trial particularly concentrates on patients with tumors harboring BRCA1/2 or PALB2 mutations, focusing primarily on heavily pretreated cases where substantial unmet medical needs exist. With enrollment finalized, the next steps include detailed data review, database locking, and comprehensive statistical assessment. A clinical study report (CSR) is anticipated to be released in the first quarter of 2027.

Dr. Amit Oza, who leads the exploratory advanced ovarian cancer cohort reported preliminary findings, indicated that CX-5461 demonstrated promising antitumor activity, achieving a disease control rate of nearly 60% in patients, all of whom had undergone prior treatments with PARP inhibitors.

The Phase 1b trial is specifically designed for patients with advanced DNA repair-deficient solid tumors, which encompass cancer types such as pancreatic, breast, and ovarian cancers. These patients typically have pursued a median of six lines of therapy, thus illustrating the critical demand for new treatment options.

Senhwa's Chief Executive Officer highlighted the achievement of completing enrollment as a crucial step forward, emphasizing the importance of the forthcoming data analysis in determining the next paths for CX-5461’s development. The drug’s unique mechanism, a first-in-class G-quadruplex stabilizer, distinguishes it from traditional PARP inhibitors by targeting DNA repair deficiencies through different cellular pathways.

Clinical Implications and Future Directions

The findings from this trial are expected to guide future clinical decisions, including potential treatment combinations, biomarker-based patient selections, and overarching strategies for the next phase of CX-5461’s development. The ongoing treatment may also lead to continued patient engagement, allowing those who benefit from the trial to enter a protocol-defined extension phase for additional follow-up and treatment.

As resistance to existing therapies, particularly PARP inhibitors, continues to be a challenge in treating HRD-associated malignancies, there is a growing imperative for innovative drugs like CX-5461. Senhwa’s ability to provide effective solutions for patients who have exhausted conventional therapies will be pivotal as the landscape of cancer treatments evolves beyond monotherapy.

Senhwa intends to leverage these findings to explore global licensing opportunities and forge strategic partnerships that could enhance potential treatment avenues for patients worldwide. The ongoing research emphasizes the commitment to advancing precision oncology, specifically targeting the unique needs of patient populations facing advanced solid tumors.

In summary, with the completion of patient enrollment in this pivotal trial, Senhwa Biosciences is poised for important developments in cancer therapy, particularly for those afflicted with challenging tumors related to DNA repair deficiencies. With expected outcomes in the coming months, the future of CX-5461 looks promising for both the company and the patients it aims to serve.